

ACAAI COVID-19 VACCINE COMPARISON CHART – 02/24/22

Vaccine	Pfizer-BioNTech	Moderna	J& J Vaccine
Mechanism of action	Vaccine contains 30 mcg of a nucleoside-modified messenger RNA (mod RNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2	Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.	Replication-incompetent adenovirus type 26 (Ad26)- vector vaccine encoding a stabilized variant of the SARS-CoV-2 S protein
Dose	0.3 ml for 12 years and up 0.1 ml for 5-11 years	0.5 ml – primary series 0.25 ml – boosters	0.5 ml
Schedule	2 doses, 21 days apart. Additional primary dose at least 28 days after the initial 2 doses is recommended for moderately and severely immunocompromised people ages 5+. Booster – 5 months after vaccination series for 12+. Mix and match dosing allowed for 18+.	2 doses, 28 days apart. Additional primary dose at least 28 days after the initial 2 doses is recommended for moderately and severely immunocompromised people. Booster – 5 months after vaccination series, mix and match dosing allowed for 18+.	1 dose. Booster – 2 months after vaccination series, mix and match dosing allowed for 18+.
Storage	1.Vials must be kept frozen between -80°C to -60°C (-112°F to -76°F) and protected from light. 2.If an ultra-low temperature freezer is not available, the thermal container may be used as temporary storage 3. Thaw and then store undiluted vials in the refrigerator [2°C to 8°C (35°F to 46°F)] for up to 5 days (120 hours) 4 For immediate use, thaw undiluted vials at room temperature [up to 25°C (77°F)] for 30 minutes. 5. Undiluted vials may be stored at room temperature for no more than 2 hours.	1.Vaccine multiple-dose vials are stored frozen between -25° to -15°C (-13° to 5°F) protected from light. 2.Do not store on dry ice or below -40°C (-40°F). 3.Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use. 4.Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours. 5. After the first dose has been withdrawn, the vial should be held between 2° to 25°C (36° to 77°F). Discard vial after 6 hours. Do not refreeze	1.Stored at 2°C to 8°C (36°F to 46°F)] in a multi-dose vial containing 5 doses, protected from light. 2.Unpunctured vials may be stored between 9°C to 25°C (47°F to 77°F) for up to 12 hours. 2. After withdrawal of first dose, the vial should be held between 2° to 8°C (36° to 46°F) for up to 6 hours or at room temperature for up to 2 hours.

ACAAI COVID-19 VACCINE COMPARISON CHART – 02/24/22

Age approved	5 and up	18 and up	18 and up
VAERS	Mandatory Reporting of adverse events Including MIS, hospitalization/ fatal COVID	Mandatory Reporting of adverse events including MIS, hospitalization/ fatal COVID	Mandatory Reporting of adverse events including MIS, hospitalization/ fatal COVID
Safety Patient self-reporting	Vsafe	Vsafe	Vsafe
Adverse events			
Solicited adverse reactions within 7 days after each dose.	Lasted 2-3 days, more adverse reactions after second dose Dose (%) 1 2 Pain at site 83.1. 78.0 Fatigue 47.4 59.4 Headache 41.9 51.7 Myalgia 21.3 37.3 Chills 14.0 35.1 Arthralgia 11.0. 21.9	Lasted 2-3 days, more adverse reactions after second dose Dose(%) 1 2 Pain at site 86.9 89.9 Fatigue. 38. 67.6 Headache 24.5. 19.3 Myalgia. 23.7 61.6 Chills 9.2 8.6 Arthralgia 16.6 45.5	(%) Pain 48.6% Erythema 7.3 Swelling 5.3 Headache 38.9 Fatigue 38.2 Myalgia 33.2 Nausea 14.2 Fever 9.0
Unsolicited	a) 12 cases of appendicitis reported b) Anaphylaxis -reported after EUA with first dose c) Myocarditis and pericarditis particularly following second dose d) Syncope e) Immunocompromised persons may have diminished response	a) 3 cases of Bell’s palsy reported 22,28, 32 days after vaccination – b) 2 cases Facial swelling in vaccine recipients with history of dermatological fillers in 1-2 days c) 1 case of nausea, vomiting 1 day after vaccination d) allergic reaction being investigated after EUA with first dose e) large local vaccine site reaction onset after day 7/8 f) Myocarditis and pericarditis particularly following second dose g) Immunocompromised persons may have diminished response	a) embolic and thrombotic events-0.06% of vaccine recipients b) Tinnitus was reported in 6 vaccine recipients c) angioedema 0.2% of vaccine recipients d) urticaria e) arthritis (0.5%) f) peripheral neuropathy (0.2%) e) Guillain Barre Syndrome f) Thrombosis with thrombocytopenia syndrome (TTS) are rare side effects
Ingredients	1. Lipids - 0.43 mg (4-hydroxybutyl) azanediyl), bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg	1. Lipids- 1.93 mg (SM-102, polyethylene glycol [PEG] 2000,dimyristoyl glycerol [DMG],	1.Polysorbate 80 2. Citric acid mono hydrate

ACAAI COVID-19 VACCINE COMPARISON CHART – 02/24/22

	2[(polyethylene glycol)-2000], N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, 0.2 mg cholesterol) 2. 0.01 mg potassium chloride 3. 0.01 mg monobasic potassium phosphate 4. 0.36 mg sodium chloride 5. 0.07 mg dibasic sodium phosphate dihydrate, 6. 6 mg sucrose	cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]) 2. 0.31 mg tromethamine, 3. 1.18 mg tromethamine hydrochloride, 4. .043 mg acetic acid, 0.12 mg sodium acetate 5. 43.5 mg sucrose.	3. Trisodium citrate dihydrate 4. Hydroxypropyl Sodium chloride 5. Sodium hydroxide 6. Hydrochloric acid
--	---	--	---

CDC note: In most situations, Pfizer-BioNTech or Moderna COVID-19 vaccines are preferred over the Janssen COVID-19 Vaccine for primary and booster vaccination.